(NASDAQ: KZIA) Kazia Therapeutics's forecast annual revenue growth rate of -13.01% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.39%.
Kazia Therapeutics's revenue in 2025 is $1,625,509.On average, 1 Wall Street analysts forecast KZIA's revenue for 2026 to be $3,994,209, with the lowest KZIA revenue forecast at $3,994,209, and the highest KZIA revenue forecast at $3,994,209. On average, 1 Wall Street analysts forecast KZIA's revenue for 2027 to be $2,662,806, with the lowest KZIA revenue forecast at $2,662,806, and the highest KZIA revenue forecast at $2,662,806.
In 2028, KZIA is forecast to generate $85,209,801 in revenue, with the lowest revenue forecast at $85,209,801 and the highest revenue forecast at $85,209,801.